Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTFHPI)

• Drug Name: Phosphonothreonine Drug Info
• Synonyms: phosphothreonine; O-phospho-L-threonine; 1114-81-4; L-Threonine O-phosphate; (2S,3R)-2-amino-3-(phosphonooxy)butanoic acid; O-Phosphothreonine; L-Threonine phosphate; Threoninium dihydrogen phosphate; O-phosphono-L-threonine; L-Threonine O-3-phosphate; O3-phosphothreonine; PHOSPHONOTHREONINE; 27530-80-9; threonine phosphate ester; (2S,3R)-2-amino-3-hydroxybutanoic acid 3-phosphate; Threonine, O-phosphono-; H-Thr(PO3H2)-OH; C4H10NO6P; phospho-l-threonine; EINECS 214-217-5; Synonyms Sources; (S)-2-Amino-3-hydroxybutanoic acid

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 10976469
  CAS Number: CAS 96193-69-0
  TTD Drug ID: DMTFHPI

Molecule-Related Drug Atlas

Drug(s) Targeting Rhodopsin (RHO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[1]
B-Octylglucoside	DMMO75G	Discovery agent	N.A.	Investigative	[1]
L-serine-O-phosphate	DMTJ1NH	Discovery agent	N.A.	Investigative	[1]
Beta-D-Mannose	DMHIG9K	Discovery agent	N.A.	Investigative	[1]
Hexadecanoic acid	DMWUXDZ	Discovery agent	N.A.	Investigative	[1]
NSC-88915	DM9WIHJ	Solid tumour/cancer	2A00-2F9Z	Investigative	[2]
Lauryl Dimethylamine-N-Oxide	DM3W2OE	Discovery agent	N.A.	Investigative	[1]
B-2-Octylglucoside	DMEGX8H	Discovery agent	N.A.	Investigative	[1]
(Hydroxyethyloxy)Tri(Ethyloxy)Octane	DMY6FUD	Discovery agent	N.A.	Investigative	[1]
B-Nonylglucoside	DM48VJR	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting Protein kinase C theta (PRKCQ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sotrastaurin acetate	DME53YS	Renal transplantation	NE84	Phase 2	[4]
RO-320432	DMFZ1YW	N. A.	N. A.	Terminated	[5]
LY-317644	DMM20PI	N. A.	N. A.	Terminated	[6]
CDE-6960	DMA0DKI	Inflammation	1A00-CA43.1	Terminated	[7]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[8]
LY-326449	DMN53M4	Discovery agent	N.A.	Investigative	[9]
L-serine-O-phosphate	DMTJ1NH	Discovery agent	N.A.	Investigative	[1]
[2,2':5',2'']Terthiophen-4-yl-methanol	DMRQC1F	Discovery agent	N.A.	Investigative	[10]
4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol	DM8IYG1	Discovery agent	N.A.	Investigative	[11]
2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile	DMNGW1A	Discovery agent	N.A.	Investigative	[11]

Drug(s) Targeting Cyclin-dependent kinase 7 (CDK7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R-roscovitine	DMSH108	Non-small-cell lung cancer	2C25.Y	Phase 2	[12]
Samuraciclib	DM54FQA	Breast cancer	2C60-2C65	Phase 1/2	[13]
SNS-032	DMEITAS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[14]
BTX-A51	DMC8XHQ	Advanced solid tumour	2A00-2F9Z	Phase 1	[15]
SY-1365	DMK48PM	Solid tumour/cancer	2A00-2F9Z	Phase 1	[16]
LY3405105	DMB51K2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[17]
SY-5609	DMNW3LH	Solid tumour/cancer	2A00-2F9Z	Phase 1	[18]
Oxazolyl methylthiothiazole derivative 1	DMZM6FW	N. A.	N. A.	Patented	[19]
Roscovitine derivative 1	DMD1G3Z	N. A.	N. A.	Patented	[19]
Tricyclic benzimidazole derivative 1	DM5SD9E	N. A.	N. A.	Patented	[19]

Drug(s) Targeting Extracellular signal-regulated kinase 2 (ERK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BVD-523	DMNB4XK	Melanoma	2C30	Phase 2	[20]
HH2710	DM0C5MV	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[21]
ASTX029	DMVZXIA	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[22]
VAN-10-4-eluting stent	DM3ZW6A	Artery stenosis	BD52	Phase 1	[23]
GDC-0994	DMFC2OY	Solid tumour/cancer	2A00-2F9Z	Phase 1	[24]
JSI-1187	DMVJWBS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[25]
LY3214996	DMFDAY7	Solid tumour/cancer	2A00-2F9Z	Phase 1	[16]
CHIR-99021	DMB8MNU	Allergic inflammation	4A80-4A85	Patented	[26]
COR-D	DMLXMCB	T-cell leukaemia	2A90	Preclinical	[27]
SB220025	DMSBUET	Arthritis	FA20	Terminated	[1]

Drug(s) Targeting MAP kinase p38 (MAPK12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SM-101	DMFX9O6	Idiopathic thrombocytopenic purpura	3B64.10	Approved (orphan drug)	[28]
VX-745	DMJAEG6	Alzheimer disease	8A20	Phase 2	[29]
ARRY-797	DMJ48AB	Dilated cardiomyopathy	BC43.0	Phase 2	[30]
KC706	DMBX6C7	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 2	[31]
SB 235699	DMNH8XU	Psoriasis vulgaris	EA90	Discontinued in Phase 1	[32]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[33]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[33]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[34]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[33]
AMP-PNP	DMTOK1D	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting Aurora kinase A (AURKA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AT9283	DMQ94CT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[35]
MLN8237	DMO8PT9	Solid tumour/cancer	2A00-2F9Z	Phase 3	[36]
PHA-739358	DMGYBZI	Prostate cancer	2C82.0	Phase 2	[12]
VX-680	DM93YKJ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[37]
ABT-348	DMMZOYN	Haematological malignancy	2B33.Y	Phase 2	[38]
ENMD-2076	DMJZVPB	Acute myeloid leukaemia	2A60	Phase 2	[12]
LY3295668	DM8RJTB	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[39]
HPP-607	DM5VSZR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[40]
MLN8054	DMUANF3	Solid tumour/cancer	2A00-2F9Z	Phase 1	[37]
CYC116	DMUMHXT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[41]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aurora kinase A (AURKA)	TTPS3C0	AURKA_HUMAN	Inhibitor	[1]
Cyclin-dependent kinase 7 (CDK7)	TTQYF7G	CDK7_HUMAN	Inhibitor	[1]
Extracellular signal-regulated kinase 2 (ERK2)	TT4TQBX	MK01_HUMAN	Inhibitor	[1]
MAP kinase p38 (MAPK12)	TTYT93M	MK12_HUMAN	Inhibitor	[1]
Protein kinase C theta (PRKCQ)	TT8QL1J	KPCT_HUMAN	Inhibitor	[1]
Rhodopsin (RHO)	TTH0KSX	OPSD_HUMAN	Inhibitor	[1]

References

• [1] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [2] Modulating G-protein coupled receptor/G-protein signal transduction by small molecules suggested by virtual screening. J Med Chem. 2008 Sep 11;51(17):5297-303.
• [3] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [4] Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
• [5] Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
• [6] Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025002)
• [8] Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
• [9] (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71.
• [10] Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
• [11] Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
• [12] Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
• [13] The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer. Br J Cancer. 2023 Jun;128(12):2326-2337.
• [14] Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
• [15] Clinical pipeline report, company report or official report of BioTheryX.
• [16] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [17] CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev. 2020 Sep;39(3):805-823.
• [18] Clinical pipeline report, company report or official report of Syros Pharmaceuticals.
• [19] Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
• [20] DOI: 10.1158/1538-7445.AM2015-4693
• [21] Clinical pipeline report, company report or official report of HaiHe Biopharma.
• [22] Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
• [23] WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
• [24] ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
• [25] National Cancer Institute Drug Dictionary (drug name JSI1187).
• [26] Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
• [27] Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26.
• [28] Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
• [29] P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J Inflamm (Lond). 2008 Dec 4;5:22.
• [30] Array BioPharmas ARRY-797 Meets Primary Endpoint in Clinical Proof of Concept Trial in Osteoarthritis Patients Whose Pain is Poorly Controlled by NSAIDs
• [31] KC706, an Oral p38 MAP Kinase Inhibitor, Increases HDL-C. Circulation. 2007;116:II_126.
• [32] Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity. J Med Chem. 2003 Dec 18;46(26):5651-62.
• [33] Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
• [34] Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
• [35] A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clin Cancer Res. 2015 Jan 15;21(2):267-73.
• [36] Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. Journal of Clinical Oncology, 2009:8553.
• [37] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [38] Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.
• [39] Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy. Mol Cancer Ther. 2019 Dec;18(12):2207-2219.
• [40] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936).
• [41] Clinical pipeline report, company report or official report of Cyclacel.